Mylan Can't Duck Securities Fraud Suit, Investors Say

Law360, New York (August 11, 2017, 7:51 PM EDT) -- Investors in EpiPen maker Mylan NV have pushed back against the pharmaceutical company’s bid to toss their securities fraud proposed class action, telling a New York federal court that Mylan hasn’t even challenged two of the categories of misstatements alleged in their complaint.

The investors said on Tuesday that those allegedly misleading omissions — about the government’s communication with and subsequent investigation of Mylan over its classification of EpiPen as a generic drug — will now move forward as a result, while the rest of Mylan’s...
To view the full article, register now.